Decentralized and agile pharmaceutical production using advanced high-precision robotic dosing technologies

Grant number: 101203133

Grant search

Key facts

  • Disease

    Disease X
  • Start & end year

    2025
    2028
  • Known Financial Commitments (USD)

    $3,816,388.03
  • Funder

    European Commission
  • Principal Investigator

    Niklas SANDLER
  • Research Location

    Finland
  • Lead Research Institution

    CURIFYLABS OY
  • Research Priority Alignment

    N/A
  • Research Category

    Therapeutics research, development and implementation
  • Research Subcategory

    Therapeutics logistics and supply chains and distribution strategies
  • Special Interest Tags

    N/A
  • Study Type

    Non-Clinical
  • Clinical Trial Details

    N/A
  • Broad Policy Alignment

    Pending
  • Age Group

    Not Applicable
  • Vulnerable Population

    Not applicable
  • Occupations of Interest

    Not applicable

Abstract

The project addresses a critical challenge in the European Union: the need for a more resilient, scalable, and decentralized approach to pharmaceutical manufacturing, particularly in the face of crises such as pandemics, natural disasters, and supply chain disruptions. Current centralized systems are often rigid and slow to adapt to sudden spikes in demand, leading to shortages of essential medicines and delays in treatments, putting public health at risk. This problem is further compounded by regulatory complexities, limited scalability, and inefficiencies in production workflows, particularly in decentralized settings like pharmacies and hospital pharmacies. To tackle this challenge, the project is developing an advanced decentralized agile manufacturing platform designed to enhance the production capabilities of pharmacies and hospital pharmacies across Europe. The platform leverages cutting-edge technologies such as 3D-inspired robotic dosing, RFID tracking, AI-driven analytics, workflow automation, and integrated quality control systems to streamline operations, ensure regulatory compliance, and enable rapid scalability during crises. By decentralizing pharmaceutical manufacturing and enhancing the agility of production, the platform allows for real-time responses to fluctuating demand, ensuring that essential medicines are produced efficiently, accurately, and in compliance with stringent EU regulations. This innovative solution not only improves crisis preparedness but also strengthens the overall pharmaceutical supply chain in the EU. It enables faster, more reliable production across multiple decentralized sites, reducing bottlenecks, waste, and downtime while maintaining high quality and safety standards. The project will empower healthcare providers across Europe to respond swiftly and effectively to public health emergencies, ultimately ensuring a more resilient and adaptable pharmaceutical landscape for the EU.